GEV.US

1,062.39

-1.55%↓

286.82

+2.31%↑

RTX

174.1

-1.22%↓

224.38

+1.39%↑

UNP

263.93

+0.03%↑

GEV.US

1,062.39

-1.55%↓

286.82

+2.31%↑

RTX

174.1

-1.22%↓

224.38

+1.39%↑

UNP

263.93

+0.03%↑

GEV.US

1,062.39

-1.55%↓

286.82

+2.31%↑

RTX

174.1

-1.22%↓

224.38

+1.39%↑

UNP

263.93

+0.03%↑

GEV.US

1,062.39

-1.55%↓

286.82

+2.31%↑

RTX

174.1

-1.22%↓

224.38

+1.39%↑

UNP

263.93

+0.03%↑

GEV.US

1,062.39

-1.55%↓

286.82

+2.31%↑

RTX

174.1

-1.22%↓

224.38

+1.39%↑

UNP

263.93

+0.03%↑

Home・Akcijų sąrašas・Ocugen Inc

Ocugen Inc

Uždarymo kaina

1.79 3.47

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.78

Max

1.79

Pagrindiniai rodikliai
By Trading Economics
Pajamos	2.3M -18M
Pardavimai	-1.9M -193K
Pelno marža	9,174.093
Darbuotojai	116
EBITDA	1.5M -16M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+566.49% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-08

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-8.7M 626M
Ankstesnė atidarymo kaina	-1.68
Ankstesnė uždarymo kaina	1.79

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

0.6818 / 0.74 Palaikymas ir pasipriešinimas

Ocugen Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-05 23:43; UTC

Svarbiausios naujienos

New Zealand's Unemployment Rate Falls in 1Q

2026-05-05 23:20; UTC

Karštos akcijos

Stocks to Watch: AMD, Super Micro, Arista Networks, Freshworks

2026-05-05 21:48; UTC

Uždarbis

Suncor Energy Reports Higher 1Q Profit on Increased Oil Production

2026-05-05 21:05; UTC

Įsigijimai, susijungimai, perėmimai

Canada Antitrust Watchdog Seeks to Kibosh Keyera Deal for Plains' Canada Gas Business -- 4th Update

2026-05-06 00:00; UTC

Rinkos pokalbiai

Canada Energy Minister Signals Energy Investments in the Pipeline -- Market Talk

2026-05-05 23:39; UTC

Rinkos pokalbiai

Gold Rises; Trump Pauses 'Project Freedom' to See if Iran Deal Can Be Finalized -- Market Talk

2026-05-05 22:26; UTC

Rinkos pokalbiai

AMD Data-Center Business Continues to Surge -- Market Talk

2026-05-05 22:20; UTC

Rinkos pokalbiai

AMD's AI Revolution is Still in Early Innings, Analysts Say -- Market Talk

2026-05-05 22:08; UTC

Uždarbis

Correction to "Palantir Beats Forecasts" on May 4. -- WSJ

2026-05-05 22:07; UTC

Uždarbis

AMD Stock Soars on Strong Earnings and Growing Confidence About AI -- Barrons.com

2026-05-05 21:48; UTC

Uždarbis

Pan American Silver 1Q Adj EPS $1.09 >PAAS

2026-05-05 21:48; UTC

Uždarbis

Pan American Silver 1Q Rev $1.2B >PAAS

2026-05-05 21:42; UTC

Uždarbis

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

2026-05-05 21:38; UTC

Uždarbis

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

2026-05-05 21:30; UTC

Uždarbis

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

2026-05-05 21:29; UTC

Uždarbis

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

2026-05-05 21:26; UTC

Uždarbis

Strategy Posts Wider Loss as Bitcoin Holdings Hit $64 Billion. The Stock Falls. -- Barrons.com

2026-05-05 21:25; UTC

Uždarbis

Alcon Inc. 1Q EPS 39c >ALC.EB

2026-05-05 21:25; UTC

Uždarbis

Alcon Inc. 1Q Rev $2.71B >ALC.EB

2026-05-05 21:24; UTC

Uždarbis

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

2026-05-05 21:18; UTC

Uždarbis

Mistras Backs 2026 Rev $730M-$750M >MG

2026-05-05 21:17; UTC

Uždarbis

AMD Stock Jumps on Solid Earnings. AI Continues to Drive Data Center Chips. -- Barrons.com

2026-05-05 21:15; UTC

Uždarbis

Strategy Records Loss of Nearly $13 Billion as Bitcoin Continues Decline -- WSJ

2026-05-05 21:12; UTC

Uždarbis

These Stocks Are Today's Movers: Intel, PayPal, Palantir, Shopify, Micron, Duolingo, and More -- Barrons.com

2026-05-05 21:11; UTC

Uždarbis

SSR Mining 1Q Rev $581.8M >SSRM

2026-05-05 21:10; UTC

Uždarbis

SSR Mining 1Q Adj EPS $1.15 >SSRM

2026-05-05 21:10; UTC

Uždarbis

SSR Mining 1Q EPS $1.16 >SSRM

2026-05-05 21:08; UTC

Uždarbis

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

2026-05-05 21:01; UTC

Uždarbis

Intact Financial 1Q EPS C$4.12 >IFC.T

2026-05-05 21:01; UTC

Karštos akcijos

Stocks to Watch Recap: Palantir, AMD, Intel, HSBC -- WSJ

Akcijų palyginimas

Kainos pokytis

Ocugen Inc Prognozė

Kainos tikslas

By TipRanks

566.49% į viršų

12 mėnesių prognozė

Vidutinis 12.33 USD 566.49%

Aukščiausias 22 USD

Žemiausias 8 USD

Remiantis 6 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Ocugen Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

6 ratings

Pirkti

Laikyti

Parduoti

Remiantis 6 analitikų, pateikusių Ocugen Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

0.6818 / 0.74Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There are no events.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.